Month: February 2026

STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine candidate SVF-001, SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer. Raheleh Nassaji brings nearly two decades of global experience across big pharma, biotech, and healthcare innovation. She combines scientific depth with strategic leadership in clinical development, capital strategy, and business development. Most recently, she...

TransUnion’s latest quarterly report finds regular insurance shopping the new normal CHICAGO, Feb. 10, 2026 (GLOBE NEWSWIRE) — Insurance shopping is now a routine activity for consumers rather than a rare event prompted by a car or home purchase. TransUnion (NYSE: TRU) analysts drew this conclusion after tracking three years of steadily increasing insurance shopping rates in the quarterly Insurance Personal Lines Trends and Perspectives Report. Most recently, 2025 fourth quarter data showed that elevated shopping levels continued throughout a season in which shopping rates typically decline. Auto insurance shopping was up 11% in Q4 2025, compared to the same period in 2024, while property insurance shopping increased 5%. “At this point we can safely say that regular insurance shopping is just the new normal,” said Patrick Foy,...

BEIJING, Feb. 10, 2026 (GLOBE NEWSWIRE) — Autozi Internet Technology (Global) Ltd. (Nasdaq: AZI) (“Autozi” or the “Company”) today announced the completion of negotiations for a landmark acquisition of approximately $1.87 billion in premium digital assets from a globally leading crypto-asset institution (the “Crypto Titan”) for a total consideration of approximately $1.1 billion. Executed amidst a period of adjustment in the global crypto market, this transaction showcases AZI’s forward-looking strategic vision and superior asset allocation capabilities. To accelerate the development of its global specialized vehicle and aftermarket parts sales network via its cross-border supply chain platform, AZI recognizes the imperative to solve the critical challenge of online cross-border payments—a...

Key Appointment to Drive Commercialization Strategy as Markets Ramp and Company Generates Initial Sales GOLETA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has named Bouchaib Nessar as its Senior Vice President of Business Development and Product to lead its go-to-market strategy across communication, sensing, and quantum markets. Bouchaib (Bouch) Nessar brings three decades of experience commercializing semiconductor photonics solutions across optical networking and data centers, sensing, and quantum. A proven leader in the field, Mr. Nessar previously held key roles at JDS Uniphase (now Lumentum), overseeing sales, product...

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions. The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara...

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories...

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced that senior management will host a conference call on Tuesday, March 10, 2026 at 8:30 a.m. ET to discuss the REIT’s fourth quarter 2025 results. Fourth Quarter 2025 Results Conference Call and WebcastDATE: Tuesday, March 10, 2026TIME: 8:30 a.m. ETINSTANT JOIN BY PHONE: Conference Call Registration (Click the URL to join the conference call by phone)Please register at least 10 minutes before the start of the call. Upon registration, an email will be sent, including dial-in details and a unique conference call access code required to join the live call.LIVE WEBCAST:Q4 2025...

ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company’s website at www.axogeninc.com. About Axogen Axogen (Nasdaq: AXGN) is focused on the...